Literature DB >> 25261092

Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma.

Hideaki Nitta1, Yasuhito Terui1, Masahiro Yokoyama1, Yuko Mishima1, Noriko Nishimura1, Kyoko Ueda1, Yoshiharu Kusano1, Naoko Tsuyama2, Kengo Takeuchi3, Yoshinobu Kanda4, Kiyohiko Hatake5.   

Abstract

Recently, elevated peripheral blood monocyte counts at diagnosis have been shown to be an independent marker associated with poor prognosis in patients with both non-Hodgkin and Hodgkin lymphoma. In this study, we retrospectively analyzed the data from a total of 550 patients with diffuse large B-cell lymphoma and evaluated the relationship between central nervous system relapse and absolute monocyte counts at diagnosis. Twenty-six patients developed central nervous system relapse. The central nervous system relapse-free survival rate was significantly lower in patients with the absolute monocyte counts ≥ 0.51 × 10(9)/L (87.8% versus 96.4%; P<0.001). This association was independently significant after adjusting for other significant factors, including systemic relapse as a time-dependent covariate by multivariate analysis (hazard ratio 2.46; 95% confidence intervals 1.05-5.75; P=0.039). These results suggest that the absolute monocyte count at diagnosis is an independent significant risk factor for central nervous system relapse in patients with diffuse large B-cell lymphoma. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Year:  2014        PMID: 25261092      PMCID: PMC4281317          DOI: 10.3324/haematol.2014.114934

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  21 in total

1.  The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma.

Authors:  R A Wilcox; K Ristow; T M Habermann; D J Inwards; I N M Micallef; P B Johnston; J P Colgan; G S Nowakowski; S M Ansell; T E Witzig; S N Markovic; L Porrata
Journal:  Leukemia       Date:  2011-05-24       Impact factor: 11.528

Review 2.  Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.

Authors:  P Allavena; A Mantovani
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

3.  Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: report from the Japanese Children's Cancer and Leukemia Study Group.

Authors:  M Tsurusawa; N Katano; Y Yamamoto; T Hirota; S Koizumi; A Watanabe; T Takeda; Y Hatae; M Yatabe; J Mimaya; T Gushiken; K Nishi; K Anami; A Kikuta; H Kanegane; K Asami; K Nishikawa; I Sekine; Y Kawano; A Iwai; T Furuyama; O Ijichi; M Miyake; H Mugishima; T Fujimoto
Journal:  Med Pediatr Oncol       Date:  1999-04

4.  The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists.

Authors: 
Journal:  Pathol Int       Date:  2000-09       Impact factor: 2.534

5.  M2b monocytes predominated in peripheral blood of severely burned patients.

Authors:  Makiko Kobayashi; Marc G Jeschke; Kenji Shigematsu; Akira Asai; Shohei Yoshida; David N Herndon; Fujio Suzuki
Journal:  J Immunol       Date:  2010-11-10       Impact factor: 5.422

6.  Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma.

Authors:  Yi Lin; Michael P Gustafson; Peggy A Bulur; Dennis A Gastineau; Thomas E Witzig; Allan B Dietz
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

7.  The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma.

Authors:  Ryan A Wilcox; Kay Ristow; Thomas M Habermann; David J Inwards; Ivana N M Micallef; Patrick B Johnston; Joseph P Colgan; Grzegorz S Nowakowski; Stephen M Ansell; Thomas E Witzig; Svetomir N Markovic; Luis Porrata
Journal:  Leuk Lymphoma       Date:  2012-01-03

8.  CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Authors:  Volkmar Boehme; Norbert Schmitz; Samira Zeynalova; Markus Loeffler; Michael Pfreundschuh
Journal:  Blood       Date:  2009-01-14       Impact factor: 22.113

9.  Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment.

Authors:  Ana M Gonzalez-Angulo; Massimo Cristofanilli; Eric A Strom; Aman U Buzdar; Shu-Wan Kau; Kristine R Broglio; Terry L Smith; Gabriel N Hortobagyi
Journal:  Cancer       Date:  2004-10-15       Impact factor: 6.860

10.  A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.

Authors:  C Y Cheah; K E Herbert; K O'Rourke; G A Kennedy; A George; P L Fedele; M Gilbertson; S Y Tan; D S Ritchie; S S Opat; H M Prince; M Dickinson; K Burbury; M Wolf; E H Januszewicz; C S Tam; D A Westerman; D A Carney; S J Harrison; J F Seymour
Journal:  Br J Cancer       Date:  2014-07-29       Impact factor: 7.640

View more
  8 in total

Review 1.  Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?

Authors:  Chan Yoon Cheah; John F Seymour
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

2.  A Low Lymphocyte-to-Monocyte Ratio Predicts Unfavorable Prognosis in Pathological T3N0 Rectal Cancer Patients Following Total Mesorectal Excision.

Authors:  Wei-Wei Xiao; Lu-Ning Zhang; Kai-Yun You; Rong Huang; Xin Yu; Pei-Rong Ding; Yuan-Hong Gao
Journal:  J Cancer       Date:  2015-05-23       Impact factor: 4.207

3.  Preoperative monocyte-lymphocyte and neutrophil-lymphocyte but not platelet-lymphocyte ratios are predictive of clinical outcomes in resected patients with non-metastatic Siewert type II/III adenocarcinoma of esophagogastric junction: a prospective cohort study (the AMONP corhort).

Authors:  Jia-Wei Zhang; Lei Huang; A-Man Xu
Journal:  Oncotarget       Date:  2017-02-18

4.  Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count.

Authors:  Yan-Li Li; Zhi-Hu Shi; Xian Wang; Kang-Sheng Gu; Zhi-Min Zhai
Journal:  BMC Cancer       Date:  2019-11-06       Impact factor: 4.430

5.  A Novel Diagnostic Model for Primary Adrenal Lymphoma.

Authors:  Kai Yu; Qingping Xue; Fangli Zhou; Haoming Tian; Qiao Xiang; Tao Chen; Yan Ren
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-02       Impact factor: 5.555

6.  MTX-HOPE is a low-dose salvage chemotherapy for aged patients with relapsed or refractory non-Hodgkin lymphoma.

Authors:  Manabu Suzuki; Saburo Tsunoda; Daisuke Koyama; Shohei Ikeda; Masumi Sukegawa; Hiroshi Hojo; Masatsugu Ohta
Journal:  J Clin Exp Hematop       Date:  2021-02-06

7.  Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma.

Authors:  Simon Le Gallou; Faustine Lhomme; Jonathan M Irish; Anna Mingam; Celine Pangault; Celine Monvoisin; Juliette Ferrant; Imane Azzaoui; Delphine Rossille; Krimo Bouabdallah; Gandhi Damaj; Guillaume Cartron; Pascal Godmer; Steven Le Gouill; René-Olivier Casasnovas; Thierry Jo Molina; Roch Houot; Thierry Lamy; Karin Tarte; Thierry Fest; Mikael Roussel
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 8.786

8.  Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma.

Authors:  Y Kusano; M Yokoyama; Y Terui; N Nishimura; Y Mishima; K Ueda; N Tsuyama; H Yamauchi; A Takahashi; N Inoue; K Takeuchi; K Hatake
Journal:  Blood Cancer J       Date:  2017-04-21       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.